Patterson Companies Stock Soars Over 30% After $4.1 Billion Acquisition Deal

GuruFocus.com
12 Dec 2024

Following the announcement of a $4.1 billion acquisition by Patient Square Capital, Patterson Companies (PDCO, Financials) saw its shares soar more than 30% in premarket trading on Wednesday. Given cash values of $31.35 per share, owners should enjoy a clear premium over the firm's current trading price.

  • Warning! GuruFocus has detected 4 Warning Signs with PDCO.

Leading distributor of dentistry and animal health goods Patterson Companies reported a clear agreement to be bought by Patient Square Capital, a private equity company with a focus on healthcare. With the sale, the firm is valued at around $4.1 billion and pays cash to each shareholder $31.35 per share.

Subject to regulatory clearances and shareholder assent, the agreement is scheduled to finalize in the fourth quarter of Patterson's fiscal 2025, according a company release.

Ademi LLP, a legal company focused on shareholder rights, has taken notice of the purchase and declared an inquiry on whether Patterson's board behaved in the best interest of public shareholders and obtained a fair price for the deal.

Patterson posted its fiscal second-quarter results on December 5 before the acquisition announcement. With net revenues of $1.67 billiona meager 1.3% rise from the same time previous yearthe business said A cybersecurity hack at Change Healthcare, a third-party vendor, affected profits, hence the firm changed its projection of fiscal 2025 earnings.

This article first appeared on GuruFocus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10